GB0029524D0 - Disease treatment - Google Patents

Disease treatment

Info

Publication number
GB0029524D0
GB0029524D0 GBGB0029524.6A GB0029524A GB0029524D0 GB 0029524 D0 GB0029524 D0 GB 0029524D0 GB 0029524 A GB0029524 A GB 0029524A GB 0029524 D0 GB0029524 D0 GB 0029524D0
Authority
GB
United Kingdom
Prior art keywords
disease treatment
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0029524.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Priority to GBGB0029524.6A priority Critical patent/GB0029524D0/en
Publication of GB0029524D0 publication Critical patent/GB0029524D0/en
Priority to PCT/GB2001/005369 priority patent/WO2002045704A2/en
Priority to AU2002222125A priority patent/AU2002222125A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0029524.6A 2000-12-04 2000-12-04 Disease treatment Ceased GB0029524D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0029524.6A GB0029524D0 (en) 2000-12-04 2000-12-04 Disease treatment
PCT/GB2001/005369 WO2002045704A2 (en) 2000-12-04 2001-12-04 Prevention and treatment of tachyphylactic response
AU2002222125A AU2002222125A1 (en) 2000-12-04 2001-12-04 Prevention and treatment of tachyphylactic response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0029524.6A GB0029524D0 (en) 2000-12-04 2000-12-04 Disease treatment

Publications (1)

Publication Number Publication Date
GB0029524D0 true GB0029524D0 (en) 2001-01-17

Family

ID=9904393

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0029524.6A Ceased GB0029524D0 (en) 2000-12-04 2000-12-04 Disease treatment

Country Status (3)

Country Link
AU (1) AU2002222125A1 (en)
GB (1) GB0029524D0 (en)
WO (1) WO2002045704A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128415D0 (en) * 2001-11-27 2002-01-16 Univ Sheffield Medicaments
GB0128628D0 (en) * 2001-11-29 2002-01-23 Univ Sheffield Disease treatment
AU2003200611C1 (en) * 2002-02-22 2005-08-04 Fci Holdings Delaware, Inc. Yieldable prop
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2008156661A2 (en) * 2007-06-15 2008-12-24 Beth Israel Deaconess Medical Center BACTERIAL MEDIATED TNF-α GENE SILENCING

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409882D0 (en) * 1994-05-18 1994-07-06 Sandoz Ltd Organic compounds
US5658881A (en) * 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5998393A (en) * 1996-04-05 1999-12-07 Kang; Sewon Methods for assessing 1,25(OH)2 D3 activity in skin and for enhancing the therapeutic use of 1,25(OH)2 D3
GB9800040D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Pyrrolidine dione derivatives
US20010041706A1 (en) * 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism

Also Published As

Publication number Publication date
WO2002045704A2 (en) 2002-06-13
WO2002045704A3 (en) 2003-05-01
AU2002222125A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
GB0028264D0 (en) Well treatment
GB0028269D0 (en) Well treatment
EG22308A (en) Tobacco treatment
EP1296697A4 (en) Therapeutic agents - i
AU6282901A (en) Medical arrangement
GB0009591D0 (en) Medical combinations
PL362855A1 (en) Improved treatment
GB0011244D0 (en) Tissue regrafting
EG25829A (en) Novel treatment
GB0030845D0 (en) Novel treatment
GB0001710D0 (en) Therapeutic treatment
AU2096002A (en) Therapeutic treatment
GB0030541D0 (en) Medical uses
GB0029524D0 (en) Disease treatment
GB0026015D0 (en) Cancer treatment
GB0128628D0 (en) Disease treatment
GB0031321D0 (en) Treatment
GB0029125D0 (en) Novel treatment
GB0019728D0 (en) Novel treatment
GB2358857B (en) Coffins
GB0020669D0 (en) Alopica treatment
GB0017495D0 (en) Treatment
GB0012793D0 (en) Treatment
GB0012760D0 (en) Treatment
GB0006415D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
COOA Change in applicant's name or ownership of the application